Abstract 16126: Antihypertensive Efficacy and Safety of Aldosterone Synthase (CYP11B2) Inhibitors: A GRADE-Guided Systematic Review and Meta-Analysis with Trial Sequential Analysis
Abstract
Background: Persistent aldosterone-driven hypertension remains common despite established renin-angiotensin system blockade and mineralocorticoid receptor antagonism. Aldosterone synthase (CYP11B2) inhibition directly suppresses aldosterone biosynthesis, but its blood pressure (BP) effects across different agents and hypertensive phenotypes have not been fully defined. We evaluated whether the available randomized evidence supports a consistent antihypertensive effect at the class level. Methods: Randomized controlled trials of CYP11B2 inhibitors versus placebo or active comparators in adults with hypertension were identified through September 2025. Random-effects models pooled effects on systolic BP (SBP), diastolic BP (DBP), aldosterone concentrations, and adverse events. Certainty of evidence was rated using GRADE, and Trial Sequential Analysis (TSA) evaluated whether cumulative evidence crossed monitoring boundaries for SBP reduction. Results: Eleven RCTs (n=3,749) enrolled patients with resistant hypertension, uncontrolled hypertension, and primary aldosteronism.CYP11B2 inhibitors reduced systolic BP: –7.23 mmHg (95% CI –8.43 to –6.03) and diastolic BP: –2.85 mmHg (95% CI –3.76 to –1.94), with no heterogeneity (I 2 ≤30%) and no difference across agents (test for subgroup differences p=0.18). Aldosterone levels decreased by 3.49 ng/dL (95% CI –5.02 to –1.96). Hyperkalemia was more common with treatment (RR 4.43, 95% CI 2.40-8.19), but overall adverse events were similar between groups (RR 1.03, 95% CI 0.64-1.64). By GRADE, certainty was high for SBP reduction and moderate for aldosterone reduction. In TSA, the cumulative Z-curve crossed the superiority monitoring boundary, establishing conclusive evidence for SBP reduction at the class level. Conclusion: CYP11B2 inhibition produces consistent BP reduction with concordant suppression of aldosterone across diverse agents and hypertensive phenotypes. Hyperkalemia is the principal safety signal without an excess of serious adverse events. TSA indicates that accumulated randomized evidence is statistically conclusive for BP lowering, supporting aldosterone synthase inhibition as a validated antihypertensive mechanism and strengthening the rationale for cardiovascular and renal outcomes trials in high-risk hypertension.